Company profile
Interpharm Holdings, Inc.
OTC: IPAH · Healthcare · Medical - Pharmaceuticals
PublicHQ Hauppauge, Reports USD
#380 of 1,418 Healthcare companies by revenue65th-percentile growth
EA Score
——FH —DQ —GM —SS 57
v0.1 · 5/100 weight · pillars only
↑ listing tenure, workforce scale · ↓ market scale, Piotroski F
Methodology →Revenue TTM
$69.2M
Rev growth YoY (TTM)
-5.1%
Net income (FY)
-$14.1M
Employees
670
as of 2026-08-31
Market cap
$660
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$75.6M$75.6M2006
Net income-$14.1M-$14.1M2006
Operating income-$10.7M-$10.7M2006
Total assets$74.4M$74.4M2006
Liabilities$63.0M$63.0M2006
Equity$11.4M$11.4M2006
Revenue trend
FY1998 – FY2006 · USD
FY98
FY99
FY00
FY01
FY03
FY04
FY05
FY06
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Interpharm Holdings, Inc.’s revenue?
Interpharm Holdings, Inc. booked $75.6M in FY2006 revenue, growing 19% year over year — faster than most Healthcare companies we track, at a -18.6% net margin.
Peers · Healthcare
Sight Sciences, Inc.53DCannara Biotech Inc.76B+CytomX Therapeutics, Inc.63CLifecore Biomedical, Inc.66BAbCellera Biologics Inc.54DRecursion Pharmaceuticals, Inc.54DKey facts
CEORaj Sutaria
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersHauppauge, null
ExchangeOTC: IPAH
Employees670
IPO date2000-01-03
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.